Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

87.78 -4.02 (-4.38%)
Official Closing Price Updated: 7:00 PM EDT, Oct 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,822,255
Open 89.60
Bid (Size) 87.00 (1)
Ask (Size) 87.80 (1)
Prev. Close 91.80
Today's Range 86.96 - 89.80
52wk Range 50.45 - 100.88
Shares Outstanding N/A
Dividend Yield 2.01%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration
All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration  
Via Benzinga
Obesity Drug Wegovy's Triumph to Catapult Novo Holdings In Golden Era Of Wealth Boost
Novo Holdings, the controlling shareholder of Novo Nordisk A/S (NYSE: NVO), is bracing for a significant influx of capital stemming from the thriving success of the weight-loss drug Wegovy.  
Via Benzinga

Performance

YTD
+28.18%
+28.18%
1 Month
-7.65%
-7.65%
3 Month
+9.73%
+9.73%
6 Month
+10.71%
+10.71%
1 Year
+71.19%
+71.19%

More News

Read More
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $500 Today
Via Benzinga
Is Novo Nordisk a Good Passive Income Stock?
Via The Motley Fool
Novo Nordisk Weight Loss Drug Patent Battle Against Viatris - Emerges As Winner
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Meet Soleno Therapeutics, The Company Whose Hunger Suppressant Sent Shares Flying 505%
Via Investor's Business Daily
Why Shares of Structure Therapeutics Are Up Monday
Via The Motley Fool
Big Pharma's Weight Loss Drugs Vs. Snacking Industry: Who Will Prevail?
Via Benzinga
Stable Giants: 3 Bigwig Biotech Stocks for Consistent Returns
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 2, 2023
Via Benzinga
Cardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)
Via AB Newswire
Topics Death
Exposures Death Product Safety
What A Government Shutdown Could Mean For You
Via Benzinga
These 5 Stocks Are Setting Up This Buying Opportunity After Strong Runs
Via Investor's Business Daily
Why Shares of Structure Therapeutics Are Soaring on Friday
Via The Motley Fool
Newcomer Structure Throws Down The Gauntlet In Obesity Treatment -- Shares Soar 66%
Via Investor's Business Daily
Why Is Obesity Focused Structure Therapeutics Stock Trading Higher Today?
Via Benzinga
Novo Nordisk Targets High Demand Indian Market For Its Popular Obesity Drugs Like Wegovy
Via Benzinga
Why Abbott Says It Won't Be A Casualty Of The Weight-Loss Battle
Via Investor's Business Daily
3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals
Via InvestorPlace
Despite Being Costly, Ozempic, Wegovy Prescriptions Surge 300% Over Three Years
Via Benzinga
Diabetes Prevalence Continues To Rise – Better Therapeutics' Digital Treatment Could Help Change This Trajectory
Via Benzinga
Popular Weight Loss Drugs Ozempic and Wegovy Alert: FDA Adds Intestinal Blockage Warning
Via Benzinga
Exposures Product Safety
Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds: Today's Top Stories
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Weight Loss Drugs Like Wegovy Could Have Linked Anesthesia Complications, European Medicines Agency To Investigate
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.